← Eichor
Condition: Oligoprogressive Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Oligoprogressive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06927635
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Me
Phase 2 · 30 location(s) · Centre Francois Baclesse · NCT04299646
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After
Phase 2 · 2 location(s) · The First Affiliated Hospital of Xiamen University · NCT06676722
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
NA · 1 location(s) · British Columbia Cancer Agency · NCT06918951
SMC Radiation Oncology SABR Cohort for Oligometastasis
Phase N/A · 1 location(s) · Samsung Medical Center · NCT07121335
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
NA · 1 location(s) · University of California, Davis · NCT06103682
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT06870942
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06523673
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell L
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT03546829
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06601296
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
NA · 1 location(s) · University of California, Davis · NCT06101290
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/
NA · 14 location(s) · Robert Olson · NCT05784428
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NA · 1 location(s) · University of California, Davis · NCT06103669
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProg
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT06367972
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Phase 3 · 75 location(s) · Canadian Cancer Trials Group · NCT06686771
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Posit
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06260033
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-
NA · 5 location(s) · Jules Bordet Institute · NCT06925984
PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
NA · 1 location(s) · University Health Network, Toronto · NCT07112170
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Ster
NA · 15 location(s) · Centre Francois Baclesse · NCT05102747
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NA · 2 location(s) · Mayo Clinic · NCT06055881
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Phase 2 · 1 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT04989725
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the
Phase 2 · 7 location(s) · The Netherlands Cancer Institute · NCT05301881
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
NA · 1 location(s) · Sunnybrook Health Sciences Centre · NCT04838899
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT06585007
Stereotactic Magnetic Resonance Guided Radiation Therapy
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT04115254
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Phase 3 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT06841172
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.